Comparison of blood pressure control with amlodipine and controlled-release isradipine: an open-label, drug substitution study [0.03%]
氨氯地平与缓释异福啶换药治疗的血压控制比较：一项开放标签研究
Michael Ganz,Rasoul Mokabberi,Domenic A Sica
Michael Ganz
An open-label drug substitution study showed that controlled-release isradipine (Dynacirc-CR) can be safely substituted for amlodipine on a mg-for-mg basis in patients with mild-to-moderate hypertension. When controlled-release isradipine w...
Calcium channel blocker class heterogeneity: select aspects of pharmacokinetics and pharmacodynamics [0.03%]
钙拮抗剂类药物的异质性：药动学和药效学的某些方面
Domenic A Sica
Domenic A Sica
Calcium channel blockers (CCBs) comprise a heterogeneous group of compounds with unique structures and pharmacologic characteristics. These agents are employed in the treatment of hypertension, coronary ischemia, and/or supraventricular arr...
Management of hypertensive chronic kidney disease: role of calcium channel blockers [0.03%]
高血压肾病的治疗：钙通道阻滞剂的作用
Robert D Toto
Robert D Toto
Both the prevalence and incidence of end-stage renal disease have been increasing in the United States over the past two decades. Diabetes and hypertension are the attributable causes for more than three fourths of all new cases of end-stag...
Therapeutic considerations in the African-American patient with hypertension: considerations with calcium channel blocker therapy [0.03%]
高血压非洲裔美国患者钙离子通道阻滞剂治疗的注意事项
John M Flack,Domenic A Sica
John M Flack
African Americans have a higher prevalence, earlier onset, and more rapid progression of hypertensive end-organ disease, as well as excessive hypertensive mortality compared with other racial/ethnic groups. Most differences in hypertension ...
William J Elliott,Armin Bandari
William J Elliott
Lowering elevated blood pressure significantly reduces the risk of stroke, but whether any specific type of antihypertensive medication is better for this purpose, independent of blood pressure-lowering effects, is controversial. Compared w...
Domenic A Sica
Domenic A Sica
In search of true value [0.03%]
寻觅真正的价值
William J Kostis,Alan C Wilson
William J Kostis
New considerations relating to class effect with angiotensin-converting enzyme inhibitors--the PEACE study [0.03%]
血管紧张素转换酶抑制剂的类效应相关的新的考虑——来自PEACE研究的资料
Domenic A Sica
Domenic A Sica
Angiotensin-converting enzyme inhibitor therapy provides positive outcome benefits in a number of cardiac scenarios including congestive heart failure, postmyocardial infarction, as well as in the hypertensive patient at cardiac risk. This ...
Should we be evaluating blood pressure dipping status in clinical practice? [0.03%]
临床实践中我们是否应该评估血压昼夜节律变化情况？
Thomas G Pickering
Thomas G Pickering
Emanuel L Bravo
Emanuel L Bravo